Production (Stage)
D
Akero Therapeutics, Inc. AKRO
$46.36 -$2.61-5.33% NASDAQ
Recommendation
Prev Close
$46.36
Volume
1,769,964
Avg Vol (90D)
1,464,846
Market Cap
$3.70B
Dividend & Yield
--
52-Week Range
$17.86 - $58.40
P/E (TTM)
--
EPS (TTM)
-$3.75
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Best Biotech Stocks to Buy in 2025
5/13/2025 - MarketBeat
Patrick Lamy Sells 4,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock
5/24/2025 - MarketBeat
Akero Therapeutics (AKRO) Considers Potential Sale Amid Strategic Interest AKRO Stock News
5/23/2025 - GuruFocus
Rafferty Asset Management LLC Sells 17,797 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
5/23/2025 - MarketBeat
Akero Therapeutics (AKRO, $47.57) Moving Average Convergence Divergence (MACD) Histogram turned positive on May 20, 2025
5/21/2025 - Tickeron - Technical Analysis
Akero Therapeutics (AKRO, $47.57) price may drop as it broke higher Bollinger Band on May 20, 2025
5/21/2025 - Tickeron - Technical Analysis
Akero Therapeutics (AKRO, $47.57) Stochastic Oscillator left the oversold zone on May 20, 2025
5/21/2025 - Tickeron - Technical Analysis
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today
5/21/2025 - Insider Monkey
Akero Therapeutics Stock Rallies To 3-Month High On Buyout Report; Retail Investors Turn Bullish
5/21/2025 - Stocktwits News Feed
Akero Therapeutics (AKRO) Weighs Sale Amid Takeover Interest
5/20/2025 - GuruFocus
Akero Therapeutics (AKRO) Considers Potential Sale Following Interest AKRO Stock News
5/20/2025 - GuruFocus
Akero Therapeutics up 16% after Street Insider report on sale being considered
5/20/2025 - TipRanks Financial Blog
Akero Therapeutics up 16% after Street Insider report on sale being considered
5/20/2025 - The Fly
Akero Therapeutics exploring potential sale after approach, Street Insider says
5/20/2025 - TipRanks Financial Blog
Akero Therapeutics exploring potential sale after approach, Street Insider says
5/20/2025 - The Fly
32,150 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Tema Etfs LLC
5/20/2025 - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 10,000 Shares of Stock
5/20/2025 - Ticker Report
Akero Therapeutics, Inc. (NASDAQ:AKRO) Holdings Reduced by Deutsche Bank AG
5/20/2025 - MarketBeat
Point72 Asset Management L.P. Sells 403,643 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
5/19/2025 - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by RTW Investments LP
5/18/2025 - MarketBeat
Tema Etfs LLC Purchases New Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
5/18/2025 - Ticker Report
Point72 Asset Management L.P. Sells 403,643 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
5/17/2025 - Ticker Report
30,208 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Cubist Systematic Strategies LLC
5/17/2025 - MarketBeat
Northern Trust Corp Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
5/17/2025 - MarketBeat
3 Mid-Caps Worth Watching Closely in March 
2/28/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$306.33M
EBIT (TTM)
-$306.35M
Net Income (TTM)
-$269.44M
Balance Sheet
Total Assets (Q)
$1.16B
Total Debt (Q)
$36.23M
Total Liabilities (Q)
$72.00M
Book Value Per Share (Q)
$13.60
Cash Flow
Cash from Operations (TTM)
-$262.63M
Cash from Investing (TTM)
-$649.74M
Cash from Financing (TTM)
$474.44M
Net Change in Cash (TTM)
-$437.93M
Filings
Filing Date
Monday, May 12, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
1.36
7-Day Total Return
16.02%
30-Day Total Return
29.99%
60-Day Total Return
-5.62%
90-Day Total Return
107.80%
Year to Date Total Return
65.10%
1-Year Total Return
153.06%
2-Year Total Return
5.17%
3-Year Total Return
463.30%
5-Year Total Return
89.92%
52-week Low
Jun 05, 2024 - $17.86
52-week High
Jan 27, 2025 - $58.40
Valuation
Market Cap
$3.70B - Mid Cap
Enterprise Value
$2.60B
Price/Sales (TTM)
--
Price/Book (Q)
3.41
Dividends and Shares
Shares Outstanding
78.66M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
akerotx.com
Phone Number
650 487 6488
Address
601 Gateway Boulevard
South San Francisco, CA 94080
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed